

Enhanced Survival of LNCaP Cells Following Cryopreservation Using the CryoStor™ CS5 Preservation Solution and Corning® CellBIND® Surface

CORNING

Application Note

John M. Baust,¹ Ana Maria Pardo,² and Todd Upton²

¹BioLife Solutions, Inc., ²Corning Incorporated, Life Sciences

Abstract

Most cell cryopreservation techniques use a mixture of cell culture media, animal sera and DMSO as a freezing solution, which, combined with slow cooling rates, prevents ice crystal damage and other adverse effects associated with the freezing process¹. However, the rapid recovery of viable, functional cells able to quickly attach and grow in culture is often a problem following cryopreservation. Cells that appear to be viable immediately upon thawing are often discovered to be floating or poorly attached after 24 hours incubation. These cells usually become necrotic or enter apoptosis and, as a result, recover very slowly, if at all. Additionally, these traditional freezing solutions usually contain a protein and/or serum component which can contribute to variability in cell survival, increase contamination risks associated with using animal-derived components and add significant cost to the process.

Here we demonstrate the benefits of using the Corning CellBIND surface combined with the protein-free BioLife CryoStor CS5 freezing solution to improve the survival of LNCaP cells, a human prostate cancer cell line that is difficult to preserve and maintain due to its slow growth and poor attachment properties. The CellBIND surface is created using a process that improves the cell attachment properties of polystyrene culture vessels. It has been demonstrated to improve the recovery and attachment of LNCaP cells following cryogenic storage². The CryoStor CS5 freezing solution was developed by BioLife Solutions to improve cell survival and recovery during and following cryogenic storage^{3,4}. It contains 5% DMSO and is based on a protein-free formulation originally developed for storage of tissues and organs under hypothermic (4°C to 10°C) conditions.




Figure 1. Survival and attachment of cryopreserved LNCaP cells in T-25 flasks 24 hours post-thaw. Survival was determined using direct cell counts (hemocytometers) with results normalized to cultures grown under standard conditions (blue column). Data is an average \pm SD of 3 independent experiments performed by Corning scientists (N = 3 repetitions per group).

Methods and Materials

LNCaP cells (obtained from ATCC; CRL-1740) were cryopreserved following ATCC recommendations in either RPMI 1640 medium with 10% fetal bovine serum (FBS) and 5% DMSO (standard freezing medium) or CryoStor CS5 freezing solution. Cells were recovered from liquid nitrogen storage by thawing rapidly and plating into 25 cm² (T-25) flasks or 96-well microplates with either the Corning CellBIND surface or a standard Tissue Culture (TC)-treated surface. Growth medium was RPMI 1640 plus 10% FBS.

Results

After thawing and 24-hour incubation at 37°C in 5% CO₂, the cells were harvested from T-25 flasks and cell survival measured using a hemocytometer with viability determined by trypan blue exclusion (Figure 1). These experiments were done by Corning scientists. Cell survival (also 24-hours post-thaw) in 96-well microplates was determined based on metabolic activity using an almarBlue™ assay (Figure 2). These experiments were done by BioLife Solutions scientists. Each study was performed in triplicate and repeated three times at each study site.

Using the Corning CellBIND surface with standard freezing medium increased LNCaP survival by over 25% compared to the standard tissue culture surface. However, combining CryoStor CS5 freezing solution with the CellBIND surface showed a 58% increase in LNCaP survival over the standard cell culture surface (ANOVA, $p = 0.0013$). Similar results were observed when cultures were visualized using fluorescent microscopy; the CryoStor CS5 freezing solution, and CellBIND surface combination showed increased cell attachment compared to the standard freezing media and the standard cell culture surface (Figure 3).






Figure 2. Survival and attachment of cryopreserved LNCaP cells in 96-well microplates 24 hours post-thaw. Survival was determined using an almarBlue assay and results normalized to cultures grown under standard conditions (blue column). Data is an average \pm SD of 3 independent experiments performed by BioLife Solutions scientists (N = 3 repetitions per group).

Standard freezing medium plus
standard TC-surface



Standard freezing medium plus
Corning CellBIND surface



CryoStor CS5 freezing solution plus
Corning CellBIND surface




Figure 3. Fluorescent micrographs of cryopreserved LNCaP cells in 96-well microplates 24 hours post-thaw. Cells were cryopreserved in either traditional media + 5% DMSO or BioLife CryoStor CS5 (5% DMSO) then thawed and plated onto either Corning CellBIND surface or the standard TC-treated surface.

Conclusions

- Combining the Corning® CellBIND® surface with the BioLife Solutions CryoStor™ CS5 freezing solution resulted in significant increases in LNCaP cell survival following cryopreservation.
- CryoStor CS5 freezing solution combined with the Corning CellBIND surface eliminated the need for proteins or sera in the cryopreservation process, reducing both the costs and the risks associated with using animal-derived sera and proteins.

References

- Ryan JA. (2004) General Guide for Cryogenically Storing Animal Cell Cultures. (CLS-TC-306) available at www.corning.com/lifesciences.
- Pardo AM, Upton T, and Hoover DS. (2004) Enhanced Attachment of LNCaP Cells to the Corning CellBIND surface. (CLS-AN-048) available at www.corning.com/lifesciences.
- Baust JM, Van Buskirk R, Baust J. (2000) Cell Viability Improves Following Inhibition of Cryopreservation-Induced Apoptosis. *In vitro Cellular and Developmental Biology*, Vol. 36(4):262-270.
- Stylianou J, Vowels M, and Hadfield K. (2006) Novel Cryoprotectant Significantly Improves the Post-Thaw Recovery and Quality of HSC from CB. *Cytherapy*. Vol. 8(1):57-61.

Warranty/Disclaimer: Unless otherwise specified, all products are for research use or general laboratory use only.* Not intended for use in diagnostic or therapeutic procedures. Not for use in humans. These products are not intended to mitigate the presence of microorganisms on surfaces or in the environment, where such organisms can be deleterious to humans or the environment. Corning Life Sciences makes no claims regarding the performance of these products for clinical or diagnostic applications. *For a listing of US medical devices, regulatory classifications or specific information on claims, visit www.corning.com/resources.

Corning's products are not specifically designed and tested for diagnostic testing. Many Corning products, though not specific for diagnostic testing, can be used in the workflow and preparation of the test at the customers discretion. Customers may use these products to support their claims. We cannot make any claims or statements that our products are approved for diagnostic testing either directly or indirectly. The customer is responsible for any testing, validation, and/or regulatory submissions that may be required to support the safety and efficacy of their intended application.

CORNING

Corning Incorporated
Life Sciences

www.corning.com/lifesciences

NORTH AMERICA

t 800.492.1110
t 978.442.2200

ASIA/PACIFIC

Australia/New Zealand
t 61 427286832

Chinese Mainland
t 86 21 3338 4338

India

t 91 124 4604000

Japan

t 81 3-3586 1996

Korea

t 82 2-796-9500

Singapore

t 65 6572-9740

Taiwan

t 886 2-2716-0338

EUROPE

CSEurope@corning.com

France

t 0800 916 882

Germany

t 0800 101 1153

The Netherlands

t 020 655 79 28

United Kingdom

t 0800 376 8660

All Other European Countries

t +31 (0) 206 59 60 51

LATIN AMERICA

grupola@corning.com

Brazil

t 55 (11) 3089-7400

Mexico

t (52-81) 8158-8400